Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock ...
Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious ...
Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one ...
A new biotechnology startup is launching with plans to challenge some of the world’s best-selling eye medicines, armed with a pair of prospects already in, or approaching, clinical testing. Called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results